CNBC Television
06 Oct 2026, 22:17 UTC · 1h ago
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Impact · against what's priced in
The article suggests a potential increase in M&A activity for Chinese biotech assets by large biopharma, but lacks specific company targets or deal terms. Consequently, there is no immediate material impact on the mentioned service providers.
Scored by the NIS engine · methodology.






